<?xml version="1.0" encoding="UTF-8"?>
<p>The HPTN 052 trial was first to demonstrate that early antiretroviral (ART) initiation – referred to here as Early Assess to ART for All (EAAA) – prevents viral transmission to the uninfected partner in heterosexual HIV‐discordant couples [
 <xref rid="jia225610-bib-0002" ref-type="ref">2</xref>]. To understand if the reported efficacy of EAAA would have similar effectiveness in preventing transmission in sub‐Saharan Africa, four large community‐based trials were launched between 2011 and 2013 [
 <xref rid="jia225610-bib-0003" ref-type="ref">3</xref>, 
 <xref rid="jia225610-bib-0004" ref-type="ref">4</xref>, 
 <xref rid="jia225610-bib-0005" ref-type="ref">5</xref>, 
 <xref rid="jia225610-bib-0006" ref-type="ref">6</xref>, 
 <xref rid="jia225610-bib-0007" ref-type="ref">7</xref>, 
 <xref rid="jia225610-bib-0008" ref-type="ref">8</xref>]. These trials demonstrated that there are significant implementation barriers to EAAA for reducing HIV incidence in high‐prevalence resource‐limited settings.
</p>
